Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

(2014) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary

(2013) Alan Garber et al.   Endocrine Practice

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

(2011) S. Madsbad et al.   DIABETES OBESITY & METABOLISM

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

(2011) Vanita R. Aroda et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Albiglutide

(2010) J. Rosenstock et al.   DRUGS OF THE FUTURE

Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

(2010) et al.   Journal of Diabetes Investigation

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE